Novartis | NVS - Current Assets


Novartis reported $28.75B in Current Assets for its fiscal quarter ending in September of 2026.





Current Assets Change Date
AbbVie USD 37.48B 3.81B Sep/2026
Amgen USD 34.36B 598M Sep/2026
AstraZeneca USD 31.45B 3.48B Sep/2026
Bausch Health Companies USD 7.41B 886M Sep/2026
Biogen USD 7.58B 278.7M Sep/2026
Bristol-Myers Squibb USD 29.77B 1.19B Sep/2026
Canopy Growth CAD 506.36M 23.1M Jun/2026
Corcept Therapeutics USD 533.87M 94.2M Sep/2026
Drreddys Laboratories INR 297.58B 4.4B Sep/2026
Eli Lilly USD 65.26B 591M Sep/2026
Gilead Sciences USD 16.55B 4.02B Sep/2026
GlaxoSmithKline GBP 17.9B 336M Sep/2026
Glaxosmithkline GBP 17.9B 134M Sep/2026
J&J USD 56.35B 3.42B Sep/2026
Merck USD 38.94B 2.26B Sep/2026
Novartis USD 28.75B 1.4B Sep/2026
Novartis USD 28.75B 2.14B Sep/2026
Pacira USD 10.3B 9.68B Sep/2026
Perrigo USD 2.4B 49.7M Sep/2026
Pfizer USD 45.01B 3.65B Sep/2026
Phibro Animal Health USD 945.17M 9.67M Sep/2026
Prestige Brands USD 492.13M 4.69M Sep/2026
Roche Holding CHF 35.44B 3.29B Jun/2026
Sanofi EUR 33.21B 1.68B Sep/2026
Sanofi EUR 31.52B 1.36B Jun/2026
Supernus Pharmaceuticals USD 711.21M 12.28M Sep/2026
Zoetis USD 6.29B 63M Sep/2026